Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.T. Lau, M.F. Khokhar, E. Doo.
Long term therapy of chronic hepatitis B with lamivudine.
Hepatology, 32 (2000), pp. 828-834
[2.]
P. Marcellin, T.T. Chang, S.G. Lim, et al.
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
N Engl J Med, 348 (2003), pp. 808-816
[3.]
G. Fattovich.
Natural history and prognosis of hepatitis B.
Semin Liver Dis, 23 (2003), pp. 47-58
[4.]
R.P. Beasley.
Hepatitis B virus. The major aetiology of hepatocellular carcinoma.
Cancer, 61 (1988), pp. 1942-1956
[5.]
H.I. Yang, S.N. Lu, Y.F. Liaw.
Hepatitis B e antigen and the risk of hepatocellular carcinoma.
N Eng J Med, 347 (2002), pp. 168-174
[6.]
T. Pollicino, G. Squadrito, G. Cerenzia, et al.
Hepatitis B virus maintains its prooncogenic properties in the case of occult HBV infection.
Gastroenterology, 126 (2004), pp. 102-110
[7.]
G.V. Papatheodoridis, E. Manesis, S.J. Hadziyannis.
The longterm outcome of interferon-alfa treated and untreated patients with HBeAg-negative chronic hepatitis B.
J Hepatol, 34 (2001), pp. 306-313
[8.]
V.W.S. Wong, H. Chan, M. Wong, N. Leung.
Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B?.
J Hepatol, 36 (2002), pp. 177
[9.]
M.G. Peters, H.W. Hann, P. Martin, et al.
Adefovir dipivoxil (ADV) alone and in combinations with lamivudine (LAM) suppresses Lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis.
J Hepatol, 293 (2002), pp. 305-313
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
